INmune Bio
INMB | NASDAQ
$0.95
-$0.10 (-9.52%)
At close: Nov 16, 2026, 4:00 PM ET
$0.95
$0.00 (-0.38%)
After-hours:
Nov 16, 2026, 7:30 PM ET
INmune Bio Company Profile
Company profile explainedCompany Profile
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Key Executives
| Name | Position |
|---|---|
| David J. Moss | President, Chief Executive Officer, Treasurer, Secretary & Director |
| Cory Randall Ellspermann | Interim Chief Financial Officer |
| Daniel Frederick Carlson | Head of Investor Relations |
| Joshua S. Schoonover | General Counsel |
| Mark William Lowdell | Co-Founder, Chair of Scientific Advisory Board, CSO & Chief Manufacturing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 29, 2026 | 424B5 | Filing |
| Oct 21, 2026 | 8-K | Current Report |
| Sep 23, 2026 | 4 | Filing |
| Sep 23, 2026 | 3 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 16, 2026 | 3 | Filing |
| Sep 14, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Jul 31, 2026 | 8-K | Current Report |
INmune Bio
| Country | United States |
| IPO Date | Feb 4, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | David J. Moss |
Contact Details
225 NE Mizner Boulevard Boca Raton,
Florida 33432 United States
Stock Details
| Ticker Symbol | INMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001711754 |
| CUSIP Number | 45782T105 |
| ISIN Number | US45782T1051 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove INMB